Inovio Pharmaceuticals Inc

NASDAQ:INOUnited States

Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.

Contact Information

Headquarters

6769 Mesa Ridge Rd.SAN DIEGO, CA, United States 92121

Phone

858-410-3134

Fax

858-404-1392

Executives

Independent Chairman of the Board

Simon Benito

President, Chief Executive Officer, Director

Jacqueline Shea

Non-Executive Independent Vice Chairman of the Board

Jay Shepard

Chief Financial Officer

Peter Kies

Chief Scientific Officer

Laurent Humeau